Navigation Links
Genomic 'markers' may head off thousands of thyroid surgeries
Date:11/23/2010

AURORA, Colo. (Nov. 22, 2010) Doctors at the University of Colorado School of Medicine were concerned recently when they found a nodule in the thyroid of a 64-year-old Colorado man. They extracted cells from the nodule, hoping to determine whether the man had cancer. But the biopsy results were inconclusive.

Even a few months ago, such uncertainty would have likely led to surgery to remove all or part of the thyroid. At least this patient would have faced a tense waiting period to see if, over time, he developed clear signs of cancer.

This time, however, the CU doctors simply sent the cell sample to a laboratory. There, a test analyzed the cells' molecular patterns, producing a result that was a relief for the patient: there was a high level of certainty he didn't have cancer.

The CU doctors are helping lead the way nationally in the use of this genomic approach to evaluating suspicious thyroid nodules. The test that benefitted the 64-year-old patient could eliminate the need for tens of thousands of unnecessary thyroid surgeries every year. The patient is willing to talk with reporters.

"This should allow many patients to avoid the cost, discomfort and risk of surgery," says Bryan Haugen, MD, who heads the Division of Endocrinology, Metabolism and Diabetes at the CU medical school.

Usually, when cells are extracted from suspicious nodules in the thyroid, they're found to be benign. No cancer. But here's the problem -- in 15-30 percent of those samples, it's hard to tell. The next step in most cases has been for a surgeon to remove part, or all, of the thyroid. That tissue is examined further. More than 70 percent of the time, there's no cancer, yet the patient had to undergo surgery to get that good news and is often subjected to lifelong thyroid hormone therapy as a result.

Haugen and the national team sought to determine if the new test could help avoid those surgeries and still identify when there's no cancer. The answer, it now turns out, is yes. The secret lies in the genes.

"When we see test results showing the right patterns we can say with a great deal of certainty that, despite initial concerns, the patient does not have cancer," Haugen says.

The test was developed by Veracyte, a California-based molecular diagnostics company. The company is marketing its thyroid test branded Afirma on a limited basis and plans additional commercialization in early 2011.

Veracyte's researchers developed the test by identifying genomic patterns that would reliably tell when a patient has no cancer present. Haugen's team at CU, along with researchers at Brigham and Women's Hospital, a part of Harvard Medical School, is now co-leading a national trial to validate Veracyte's test. The trial involves more than 40 sites that are comparing the genomic test's results to analyses by two pathology experts of tissue obtained by traditional surgery. In September Haugen presented early information to an international thyroid conference in Paris. The findings confirmed the test's premise that when certain patterns appear among 142 thyroid genes (out of tens of thousands), the odds are very high more than 95 percent that there's no cancer.

That's a probability but not a certainty. Those odds are similar, however, to when an expert pathologist looks at the cells and determines there is no cancer -- but this time without surgery.

The American Cancer Society estimates that 44,670 new thyroid cancer cases (33,930 in women, and 10,740 in men) will be diagnosed nationwide this year. Nearly two-thirds of the cases occur in people between the ages of 20 and 55. The chance of being diagnosed with thyroid cancer has doubled since 1990, in part because of better detection.


'/>"/>

Contact: Dan Meyers
dan.meyers@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Researchers chart genomic map spanning over 2 dozen cancers
2. SeqWright Advances Genomic Discovery With Isilon IQ
3. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
4. Improvements needed in genomic test result discussions
5. Breast Cancer Patients Often Confused by Genomic Testing
6. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
7. Large-scale genomic analysis of prostate cancer unveiled
8. New genomic marker for tuberculosis may help identify patients who will develop the disease
9. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
10. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
11. La Jolla Institute to develop San Diegos first center for RNAi genomics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: